BAY-60-7550 (CAS 439083-90-6)

BAY-60-7550 is a selective and potent PDE2 inhibitor, potentially useful for enhancing cAMP/cGMP-mediated object and spatial memory consolidation, with IC50 values of 2.0 nM (bovine) and 4.7 nM (human). Cyclic nucleotide phosphodiesterases (PDEs) play a role in regulating intracellular levels of the second messengers cAMP and cGMP, which are essential for signal transduction and various cellular processes. Specifically, Type 2 PDE isoforms, such as PDE2, are responsible for hydrolyzing the phosphodiester bond to inactivate cAMP and cGMP. exhibits significant selectivity for PDE2 over PDE1 (50-fold) and demonstrates even greater selectivity compared to PDE5, PDE3B, PDE4B, PDE7B, PDE8A, PDE9A, PDE10A, and PDE11A (more than 100-fold). Through its inhibition of PDE2, BAY 60-7550 enhances cGMP signaling, which has been found to counteract oxidative stress-induced anxiety-like behavioral effects in mice. Administration of BAY 60-7550 at a dose of 3 mg/kg results in increased cGMP signaling, leading to the alleviation of anxiety-like behaviors. Additionally, BAY 60-7550 at a dose of 1 mg/kg may act to improve object location task performance in rats by enhancing cAMP/cGMP-mediated object and spatial memory consolidation. In relation to adrenal health, PDEs are regulatory enzymes that modulate cAMP/cGMP levels and thus play a significant role in controlling steroidogenesis. Disruptions in PDE activity have been associated with various adrenal diseases, underscoring the importance of maintaining proper PDE function for adrenal health.